Antiretroviral News and Research RSS Feed - Antiretroviral News and Research

Study: Rate of mother to child HIV transmission is at an all-time low in the UK

The rate of mother to child HIV transmission is at an all-time low in the UK, according to a paper published today in the journal AIDS. [More]
Professor receives $17M NIH grant to support IMPAACT Network

Professor receives $17M NIH grant to support IMPAACT Network

Grace Aldrovandi, MD, CM, principal investigator at The Saban Research Institute of Children's Hospital Los Angeles, has been awarded $17 million by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. [More]
Chronic intake of marijuana protects critical immune tissue from damaging effects of HIV infection

Chronic intake of marijuana protects critical immune tissue from damaging effects of HIV infection

New evidence that chronic intake of THC, the primary psychoactive ingredient in marijuana, can protect critical immune tissue in the gut from the damaging effects of HIV infection is reported in AIDS Research and Human Retroviruses, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. [More]
CytoDyn submits PRO 140 Phase 2b trial protocol to FDA for treatment substitution in HIV patients

CytoDyn submits PRO 140 Phase 2b trial protocol to FDA for treatment substitution in HIV patients

CytoDyn Inc., a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, announced today that the Company has submitted a Phase 2b clinical trial protocol, for its lead product candidate, PRO 140, to the U.S. Food and Drug Administration for treatment substitution in patients with Human Immunodeficiency Virus (HIV). [More]

New study explores the effect of food insecurity on treating HIV-infected pregnant women in Uganda

In Uganda the prescription of three antiretroviral (ARV) drugs, which aim to suppress the virus to prevent disease progression, have resulted in huge reductions in HIV mortality rates. However, disease is not the only scourge in Uganda, and a new study in The Journal of Clinical Pharmacology explores the impact food insecurity may have on treating pregnant women. [More]
Walgreens collaborates with NMAC to improve treatment outcomes for African Americans with HIV

Walgreens collaborates with NMAC to improve treatment outcomes for African Americans with HIV

In collaboration with the National Minority AIDS Council, Walgreens is furthering its commitment to improve HIV treatment outcomes for African Americans living with HIV by deepening pharmacists' training and expanding access to the pneumococcal vaccination specifically indicated for persons living with HIV as incidents of flu and pneumonia rise. [More]
Alabama experts develop living document that includes new therapies for Hepatitis C virus

Alabama experts develop living document that includes new therapies for Hepatitis C virus

When treatment guidelines for a particular disease emerge, they are often published in a peer-reviewed medical journal, which can take up to three years. One University of Alabama at Birmingham infectious diseases expert recently helped develop new Hepatitis C virus (HCV) guidelines that can be updated and published as new data emerge and new therapies are approved. [More]
Mylan launches trastuzumab biosimilar for treatment of HER2-positive metastatic breast cancer

Mylan launches trastuzumab biosimilar for treatment of HER2-positive metastatic breast cancer

Mylan Inc. (Nasdaq: MYL), one of the world's leading generic and specialty pharmaceutical companies, today announced that its subsidiary, Mylan Pharmaceuticals Private Limited, has launched the world's first trastuzumab biosimilar in India. [More]

Researchers gain better understanding of HIV infection through electron microscopy

The human intestinal tract, or gut, is best known for its role in digestion. But this collection of organs also plays a prominent role in the immune system. In fact, it is one of the first parts of the body that is attacked in the early stages of an HIV infection. Knowing how the virus infects cells and accumulates in this area is critical to developing new therapies for the over 33 million people worldwide living with HIV. Researchers at the California Institute of Technology are the first to have utilized high-resolution electron microscopy to look at HIV infection within the actual tissue of an infected organism, providing perhaps the most detailed characterization yet of HIV infection in the gut. [More]
CONRAD receives USAID Pioneers Prize for developing tenofovir gel to reduce HIV infection in women

CONRAD receives USAID Pioneers Prize for developing tenofovir gel to reduce HIV infection in women

CONRAD, a leading reproductive health-research organization based at Eastern Virginia Medical School (EVMS), today announced that they are a winner of the United States Agency for International Development (USAID) Science and Technology Pioneers Prize for their work in developing tenofovir gel. [More]
Researchers create vaginal cream using silver nanoparticles to control transmition of HIV

Researchers create vaginal cream using silver nanoparticles to control transmition of HIV

The product has proven efficiency in lab tests, although clinical trials are yet to be performed. After discovering that silver nanoparticles are capable of blocking the entry of Human Immunodeficiency Virus (HIV) into the organism, a group of researchers from the University of Texas, in collaboration with Humberto Lara Villegas, specialist in nanoparticles and virology from the University of Monterrey, Mexico (UDEM), create a vaginal cream to control the transmition of the virus. [More]
Mylan Pharmaceuticals launches Repaglinide Tablets, 0.5 mg, 1 mg and 2 mg

Mylan Pharmaceuticals launches Repaglinide Tablets, 0.5 mg, 1 mg and 2 mg

Mylan Inc. today announced that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has launched Repaglinide Tablets, 0.5 mg, 1 mg and 2 mg. This product is the generic version of Novo Nordisk's Prandin, which is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. [More]
European Commission approves ViiV Healthcare's Tivicay for treatment of HIV infected adults

European Commission approves ViiV Healthcare's Tivicay for treatment of HIV infected adults

ViiV Healthcare today announced that the European Commission has approved Tivicay (dolutegravir), an integrase inhibitor, for use in combination with other anti-retroviral medicinal products for the treatment of HIV infected adults and adolescents above 12 years of age. [More]
Study: Pro-inflammatory molecules linked with early death in HIV patients who abuse alcohol

Study: Pro-inflammatory molecules linked with early death in HIV patients who abuse alcohol

A study led by researchers at Boston University School of Medicine (BUSM) provides new insight into the impact that pro-inflammatory molecules have on early death in HIV patients who abuse alcohol. [More]

Study: HIV-specific poison kills persisting HIV-infected cells during antiretroviral therapy

‚ÄčA team including University of North Carolina and NIH scientists has demonstrated in a mouse model that an HIV-specific poison can kill cells in which the virus is actively reproducing despite antiretroviral therapy. [More]

Researchers deploy potential new weapon against HIV

Researchers at the UNC School of Medicine have deployed a potential new weapon against HIV - a combination therapy that targets HIV-infected cells that standard therapies cannot kill. [More]
Mylan announces launch of Mycophenolic Acid Delayed-release Tablets

Mylan announces launch of Mycophenolic Acid Delayed-release Tablets

Mylan Inc. today announced that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has launched Mycophenolic Acid Delayed-release Tablets, 180 mg and 360 mg. This product is the generic version of Novartis' Myfortic Delayed-release Tablets. [More]

Zyomyx's MyT4 point-of-care CD4 diagnostic test receives CE mark approval

Mylan, Inc. today announced that Zyomyx's MyT4 point-of-care CD4 diagnostic test has received the CE Certificate of Conformity in the European Union, an important step toward launching this innovative test and expanding access to affordable, accessible and reliable diagnostics for people living with HIV globally. [More]

Merck announces FDA approval of ISENTRESS for oral suspension

Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration recently approved ISENTRESS for oral suspension, a new pediatric formulation of Merck's integrase inhibitor. With this approval, ISENTRESS is now indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in patients four weeks of age and older. [More]
C. parvum and cryptosporidiosis: an interview with Dr. Momar Ndao, McGill University

C. parvum and cryptosporidiosis: an interview with Dr. Momar Ndao, McGill University

Cryptosporidium parvum is one of the most common enteropathogens to affect humans in the world. The protozoan parasite causes a gut infection referred to as cryptosporidiosis. [More]